Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Express Scripts
AstraZeneca
Dow
Johnson and Johnson

Last Updated: November 13, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202091

See Plans and Pricing

« Back to Dashboard

NDA 202091 describes SUPRAX, which is a drug marketed by Lupin Ltd, Lederle, and Lupin Pharms, and is included in eight NDAs. It is available from five suppliers. There is one patent protecting this drug and one Paragraph IV challenge. Additional details are available on the SUPRAX profile page.

The generic ingredient in SUPRAX is cefixime. There are fourteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the cefixime profile page.
Summary for 202091
Tradename:SUPRAX
Applicant:Lupin Ltd
Ingredient:cefixime
Patents:1
Formulation / Manufacturing:see details
Pharmacology for NDA: 202091
Medical Subject Heading (MeSH) Categories for 202091
Suppliers and Packaging for NDA: 202091
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
SUPRAX cefixime FOR SUSPENSION;ORAL 202091 NDA Lupin Pharmaceuticals, Inc. 27437-207 27437-207-02 10 mL in 1 BOTTLE (27437-207-02)
SUPRAX cefixime FOR SUSPENSION;ORAL 202091 NDA Lupin Pharmaceuticals, Inc. 27437-207 27437-207-03 20 mL in 1 BOTTLE (27437-207-03)
Paragraph IV (Patent) Challenges for 202091
Tradename Dosage Ingredient NDA Submissiondate
SUPRAX FOR SUSPENSION;ORAL cefixime 202091 2014-07-22

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:FOR SUSPENSION;ORALStrength500MG/5ML
Approval Date:Feb 20, 2013TE:ABRLD:Yes
Patent:  Start TrialPatent Expiration:Dec 14, 2028Product Flag?YSubstance Flag?Delist Request?
Patented Use:METHODS FOR TREATING BACTERIAL INFECTIONS

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Medtronic
Colorcon
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.